Prion diseases are characterized by an accumulation of PrP(Sc), a misfolded
isoform of the normal cellular
prion protein, PrP(C). We previously reported the bioactivity of
acridine-based compounds against PrP(Sc) replication in
scrapie-infected
neuroblastoma cells and now report the improved potency of
bis-acridine compounds. Bis-
acridines are characterized by a dimeric motif, comprising two
acridine heterocycles tethered by a linker. A library of bis-(6-chloro-2-methoxy-acridin-9-yl) and bis-(7-chloro-2-methoxy-benzo[b][1,5]naphthyridin-10-yl) analogs was synthesized to explore the effect of structurally diverse linkers on PrP(Sc) replication in
scrapie-infected
neuroblastoma cells. Structure-activity analysis revealed that linker length and structure are important determinants for inhibition of
prion replication in cultured scrapied cells. Three
bis-acridine analogs, (6-chloro-2-methoxy-acridin-9-yl)-(3-[4-[3-(6-chloro-2-methoxy-acridin-9-ylamino)-propyl]-piperazin-1-yl]-propyl)-
amine, N,N'-bis-(6-chloro-2-methoxy-acridin-9-yl)-1,8-diamino-3,6-dioxaoctane, and (1-[[4-(6-chloro-2-methoxy-acridin-9-ylamino)-butyl]-[3-(6-chloro-2-methoxy-acridin-9-ylamino)-propyl]-carbamoyl]-ethyl)-
carbamic acid tert-butyl
ester, showed half-maximal inhibition of PrP(Sc) formation at 40, 25, and 30 nM, respectively, and were not cytotoxic to uninfected
neuroblastoma cells at concentrations of 500 nM. Our data suggest that
bis-acridine analogs may provide a potent alternative to the
acridine-based compound
quinacrine, which is currently under clinical evaluation for the treatment of
prion disease.